Medscape Medical NewsAll articles

Quantitative Total Extensible Imaging (QTxI)

AIQ Solutions, Inc. • Radiology • 07/23/2018

510(k)IEC 62304 Class C
FDA Summary PDF

Device Purpose

Quantitative Total Extensible Imaging (QTxI) is a medical software platform designed to enhance the analysis of DICOM CT and PET images by enabling medical professionals to perform quantitative assessments through image registration and Region of Interest (ROI) analysis. Its current primary application, via the Quantitative Total Bone Imaging (QTBI) module, focuses on identifying and measuring bone "hot-spots" on PET scans, utilizing 3D visualization to support diagnostic and treatment evaluation processes.

Summary

Quantitative Total Extensible Imaging (QTxI) is a software platform designed to assist trained medical professionals, such as radiologists and oncologists, in managing and evaluating digital medical images. It supports DICOM CT and PET modalities, offering tools to receive, store, retrieve, display, and process images, as well as create reports. Key functionalities include image registration, fusion, and the identification and contouring of Regions of Interest (ROIs) for subsequent analysis, aiming to enhance the efficiency and accuracy of image interpretation. The core methodology of QTxI involves quantitative and statistical analysis of full or partial body scans, achieved by registering patient images to a template space. This allows for the evaluation of quantitative changes in ROIs, supported by 3D interactive rendering of images with highlighted ROIs. Currently, its primary application module is the Quantitative Total Bone Imaging (QTBI) module, which specifically focuses on identifying and measuring "hot-spots" on PET scans. The system also incorporates Picture Archiving and Communication System (PACS) functionalities and has undergone non-clinical software verification testing to confirm it meets product performance and functional specifications, ensuring data integrity.

AI Regulatory Concerns

Powered byJev by TypeSafe AI

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

Keywords

Quantitative ImagingImage Analysis SoftwareDICOMPET ScansCT ScansRegion of Interest (ROI)Image Registration3D RenderingOncologyPACS

Device Metadata

Submission Number
K173444
Company
AIQ Solutions, Inc.
Panel
Radiology
Product Code
N/A
Data Type
Images
Clinical Function
Assessment
AI Function
Analysis
AI Subclass
quantification/feature localization

Relevant Clinical Questions

  • Q1. How does the 'registration to template space' methodology in QTxI account for anatomical variability between patients, and what is the validated accuracy of this registration for quantitative analysis?; What specific quantitative metrics does the Quantitative Total Bone Imaging (QTBI) module provide for 'hot-spots' on PET scans, and how have these metrics been validated against existing clinical standards or manual methods?; Beyond its PACS functionality, to what extent can the QTxI software be integrated with existing hospital information systems (HIS) and radiology information systems (RIS) for enhanced workflow automation?; What are the typical computational performance characteristics of QTxI, such as processing time for full-body scan analysis and 3D rendering, when operating on standard clinical workstations?; Given that QTxI is designed to support multiple image analysis modules, what are the future development plans for additional modules beyond QTBI, and which anatomical regions or disease types will they target?

Risk Classification

ESL Analysis
FDA Device ClassII

FDA Class II via 510(k) pathway; IEC 62304 Class C (software safety classification); Authorized before §524B enforcement

Learn how Parasoft automates IEC 62304 compliance testing →

Cybersecurity Evidence

Powered by SBOMator™

Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.

Cyber Score5/100
SBOM Evidence⚠ Not mentioned in summary
Cyber Risk Assessment⚠ Not mentioned in summary
Postmarket Plan⚠ Not mentioned in summary
§524B ApplicableNo

Supply Chain BOM Evidence

Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.

SBOMSoftware Bill of Materials
- Not detected
ML-BOMMachine Learning Bill of Materials
- Not detected
SaaSBOMSoftware-as-a-Service Bill of Materials(platform)
✓ Detected
HBOMHardware Bill of Materials
- Not detected
CBOMCryptography Bill of Materials
- Not detected
VDR/VEXVulnerability Disclosure Report / Vulnerability Exploitability eXchange
- Not detected
OBOMOperations Bill of Materials
- Not detected

Analysis:

• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.

• Evidence of SaaSBOM detected in AI-generated device summary.

• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.

• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.

• Not detected in AI-generated device summary: SBOM, ML-BOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.

Preparing a similar submission?

ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.

Assess Your Readiness →Or contact ESL directly
Quantitative Total Extensible Imaging (QTxI) - AIQ Solutions, Inc. | ESL FDA AI Device Intelligence